How does Worldwide ensure specialized, experienced teams execute our rare disease studies? How does patient education play into our study delivery? Watch EBD Group’s interview with Therapeutic Strategy Lead for Rare Diseases, Derek Ansel, to find out more about how we approach rare disease studies.
Authors:
Derek Ansel, MS, LCGC
Vice President, Therapeutic Strategy Lead, Rare Disease
